

**Institut Paoli Calmettes and Ipsogen presented a new study supporting the pivotal role of tumor grade in chemotherapy prescription at the 32nd Annual San Antonio Breast Cancer Symposium**

*The study reinforces tumor grade as the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size*

Marseille, France, Dec 21, 2009 – Ipsogen SA (Alternext: ALIPS) today announced that a new study confirming the pivotal role of tumor grade in chemotherapy prescription has been presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), December 9-13, 2009.

The study was conducted at Institut Paoli Calmettes (IPC) Cancer Centre, Marseille, France. Using the centre database and a classification tree method, it retrospectively examined the tumor and patient characteristics driving prescription of adjuvant chemotherapy for 5854 early stage node negative (M-/N-), invasive breast cancer (IBC) patients treated between 1999 and 2005.

The study results indicate that tumor grade is the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size. Hierarchy of factors driving chemotherapy decision is remarkably stable over time, despite the progressive availability of new pathologic indicators over time.

“These new findings further support the value of Genomic Grade -a tool to refine tumor grading by resolving intermediate histologic grade 2 tumors in which indication of chemotherapy is a clinical challenge - for treatment decision making. Integrated in currently validated treatment algorithms using tumor grade, the Genomic Grade could contribute to a more individualized chemotherapy strategy in Invasive Breast Cancer” comments Hélène Peyro-Saint-Paul, Ipsogen Chief Medical Officer.

The study was presented at Poster Session 2, Friday, Dec 11, 2009, abstract # 2089:

Title: Real-life implementation of treatment guidelines for adjuvant chemotherapy in invasive breast cancer: retrospective analysis of a large single centre 10-year database.

Jean-Marie Boher, Jean-Marc Extra, Jacques Camerlo, Carole Tarpin, Emmanuelle Charaffe-Jauffret, Eric Lambaudie, Agnes Tallet, Hélène Peyro-Saint-Paul, Patrice Viens

## About IPSOGEN

Ipsogen develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of 'companion diagnostic' tests.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in molecular profiling of cancers. It continues its efforts to identify develop and commercialize diagnostic tests that will become standard references and will have a significant impact on patients, medical professionals and society. Ipsogen employed 70 people as of June 30, 2009. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: [www.ipsogen.com](http://www.ipsogen.com)

## Contacts

### IPSOGEN

#### Vincent Fert

President and CEO

Tel: + 33 (0)4 9129 3090

[fert@ipsogen.com](mailto:fert@ipsogen.com)

### NewCap

#### Financial Communication

#### and Investor Relations

Axelle Vuillermet & Pierre Laurent

Tel: + 33 (0)1 44 71 94 93

[ipsogen@newcap.fr](mailto:ipsogen@newcap.fr)

**2009 annual revenue:**

**17 February 2010 (after market)**